Eylea Biosimilar Race Hots Up As Formycon Launches Phase III Trials
Formycon Collaborating With Partner Bioeq
Formycon has pushed its second ophthalmology biosimilar candidate into Phase III trials, the German firm’s Eylea (aflibercept) biosimilar, FYB203, which has been licensed to Bioeq. Multiple firms are now circling Eylea, ahead of a projected US market formation in 2023.
You may also be interested in...
Sandoz has revealed late-stage clinical development plans for an aflibercept biosimilar, setting out details of a Phase III trial for the proposed Eylea rival.
Korea’s Alteogen believes that formulation patents granted in the EU, US and Japan as well as a pending process patent may offer it a first-mover advantage on biosimilar aflibercept. The firm has just completed a Phase I trial for its proposed rival to Eylea.
Celltrion has announced that its latest biosimilar development project is progressing to Phase III trials, with its aflibercept rival to Eylea following recent advances for the Korean firm’s denosumab, omalizumab and ustekinumab candidates.